Pilot study to investigate whether oral phosphorus binders can reduce FGF23 levels and can influence vascular function as measured by pulse wave velocity in patiens with chronic kidney disease stage 3 (eGFR 30-60 ml/min/1,73 m2).
- Conditions
- chronic kidney diseaseCKDrenal failure10029149
- Registration Number
- NL-OMON36731
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1.patients with eGFR 30-60 ml/min/1,73 m2
2.serum phosphorus level <1,49 mmol/L and >0,9 mmol/L
3.age >18 year
4.informed consent
Exclusion Criteria
1. known allergy or intolerance for sevelamer-containing drugs
2. patients with heart failure
3. Use of phosphate binder therapy
4. Patients dependent on tube-feeding or those with malabsorption syndrome
5. rapidly deteriorating renal function
6. pregnant woman
7 patient with kidney transplantation
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Serum FGF23 and phosphaturia before and after 8 weeks of treatment with<br /><br>sevelamer-carbonate and change in PWV</p><br>
- Secondary Outcome Measures
Name Time Method <p>Pulse Wave Velocity measured before and after the treatment with Sevelamer.</p><br>